News

Boosting the levels of irisin, a protein found at lower levels in people with pulmonary arterial hypertension (PAH), may help slow disease progression by stopping abnormal cell growth and blood vessel remodeling in the lungs, a study has found. “[I]risin is a novel protective factor against PAH development and is…

Elevated blood levels of a protein called CTRP7 — which are significantly higher in people with pulmonary arterial hypertension (PAH) than in those without the disease — may predict a poor response to Uptravi (selexipag), according to findings from a new study in Japan involving both mice and…

Balloon pulmonary angioplasty (BPA) led to significant clinical improvements for people with chronic thromboembolic pulmonary hypertension (CTEPH) when used as an initial therapy or after a pulmonary endarterectomy (PEA) surgery, according to a global observational study. “Our data are in line with previous reports on changes of clinical and…

The rates of long-term survival and perioperative complications after a lung transplant in people with group 2 or group 3 pulmonary hypertension (PH) aren’t significantly different from those in people who don’t have PH, a study reports. “No significant differences [between group 2 PH, group 3 PH, or no…

Researchers used small particles called extracellular vesicles to deliver a form of apelin directly to damaged blood vessels in the lungs, which helped reverse the damage and improve heart function in animal models of pulmonary arterial hypertension (PAH), according to a study. Apelin, a peptide that plays a role…

Providing a protein called BMPER that is found at low levels in models of pulmonary arterial hypertension (PAH) may ease disease progression, a study suggests. “Our study identifies BMPER as a novel therapeutic target for pulmonary arterial hypertension and provides new insights into the underlying mechanisms of the disease,” researchers wrote.

People with pulmonary arterial hypertension (PAH) with at least one coexisting condition associated with cardiovascular disease had similar rates of hospitalization and mortality as those without these conditions after a combination treatment of macitentan and tadalafil, according to a real-world analysis. There was, however, a tendency towards more adverse…

Following the first commercial sale of Yutrepia (treprostinil) inhalation powder to treat certain types of pulmonary hypertension, the therapy’s maker, Liquidia, has received an additional $50 million under its financing agreement with Healthcare Royalty (HCRx). Per that HCR Agreement, Liquidia has been raising funds by selling HCRx…

A Phase 3 clinical trial testing the experimental daily oral treatment ralinepag in people with pulmonary arterial hypertension (PAH) has completed enrollment. The ADVANCE OUTCOMES trial (NCT03626688) enrolled 728 people with PAH who were on oral background therapies. Participants are being randomly assigned to receive ralinepag at doses…

Adding Winrevair (sotatercept-csrk) to background treatment significantly reduces the risk of clinical worsening in people with a recent pulmonary arterial hypertension (PAH) diagnosis, according to results from a Phase 3 clinical trial. The therapy led to “a statistically significant and clinically meaningful reduction in the risk of clinical…

Enrollment is now complete — with nearly 400 participants with pulmonary arterial hypertension (PAH) — in the Phase 3 PROSERA clinical trial that’s testing the PAH treatment candidate seralutinib against a placebo in adults. Top-line results from PROSERA are expected in February 2026, according to Gossamer Bio, which is…

The U.S. Food and Drug Administration (FDA) has accepted Gradient Denervation Technologies, a company that makes an ultrasound-based catheter to treat pulmonary hypertension (PH), into a program to facilitate development of medical devices. Acceptance into the FDA’s Total Product Life Cycle Advisory Program (TAP) pilot will give…